{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-13T05:20:34.517092+00:00","company":{"ticker":"ITRMF","cik":1659323,"company_name":"Iterum Therapeutics plc"},"pagination":{"limit":100,"returned":31,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"lender":[{"display_name":"Pfizer Inc.","detail":"unknown","count":1,"first_seen":"2025-05-19T23:59:59+00:00","last_seen":"2025-05-19T23:59:59+00:00","evidence_fact_ids":[86762]}]},"facts":[{"fact_type":"debt_financing","fact_key":"fafbae1225470a2c9cbc9dab1ba449d2a43d9b9a","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2026-03-27T23:59:59+00:00","payload":{"counterparty":null,"effective_date":"2026-03-27","event":"default","instrument_type":"senior_notes","interest_rate_text":"prime rate of interest quoted by Bloomberg on such date or on the most recent da","item_codes_triggered":["2.04"],"maturity_text":null,"principal_text":null},"claim":"Iterum Therapeutics plc reported a default on senior notes at prime rate of interest quoted by Bloomberg on such date or on the most recent da.","evidence_excerpt":"The filing of the Winding Up Petition described in Item 1.03 above constitutes an event of default under the Company’s Limited Recourse Royalty-Linked Subordinated Notes, dated as of January 21, 2020 (the “Royalty-Linked Notes”), issued pursuant to an Indenture between Iterum Therapeutics Bermuda Limited, as the note issuer, the Company, Iterum Therapeutics International Limited, Iterum Therapeutics US Limited and Iterum Therapeutics US Holding Limited, as guarantors, Iterum Holders’ Representative LLC, as holders’ representative, and Computershare Trust Company, N.A., as trustee.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-127785","anchor_url":"https://secwatch.observer/filing/0001193125-26-127785#claim-fafbae1225470a2c9cbc9dab1ba449d2a43d9b9a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000119312526127785/0001193125-26-127785-index.htm"},{"fact_type":"distress_event","fact_key":"8bbcbac177175482b1446af57a3db7caa2503f56","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2026-03-27T23:59:59+00:00","payload":{"case_number":null,"court":"High Court in Ireland","item_codes_triggered":["1.03"],"petition_date":"2026-03-27","proceeding_type":"other"},"claim":null,"evidence_excerpt":"On March 27, 2026, Iterum Therapeutics plc (the “Company”) filed a petition in the High Court in Ireland to wind up the Company (the “Winding Up Petition”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-127785","anchor_url":"https://secwatch.observer/filing/0001193125-26-127785#claim-8bbcbac177175482b1446af57a3db7caa2503f56","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000119312526127785/0001193125-26-127785-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"d4b0ae3d9b1c36a4afe563fff58b8c7a90d152dc","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2026-03-02T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-02-24","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5550(b)(2)","5550(b)(1)","5550(b)(3)"],"rules_cited_in_text":true},"claim":"Iterum Therapeutics plc received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(2), 5550(b)(1), 5550(b)(3)).","evidence_excerpt":"February 24, 2026, Iterum Therapeutics plc (the “Company”) received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). The Determination Letter indicated that, as a result of the Company’s previously disclosed and continued noncompliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”) for continued listing on The Nasdaq Capital Market, the Company’s ordinary shares will be scheduled for delisting and will be suspended from trading on Nasdaq effective","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-085646","anchor_url":"https://secwatch.observer/filing/0001193125-26-085646#claim-d4b0ae3d9b1c36a4afe563fff58b8c7a90d152dc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000119312526085646/0001193125-26-085646-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"a7a323870089529d2a8fd73df21673cb84cf4379","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2025-12-12T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2026-02-23","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-08-25","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Iterum Therapeutics plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"August 25, 2025, Nasdaq notified the Company that it no longer satisfied Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”) for continued listing on The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq granted the Company 180 calendar days, through February 23, 2026, to regain compliance with the Bid Price Rule, which requires that the closing bid price of the Company’s ordinary shares be at least $1.00 for a minimum of 10 consecutive business days. The Company remains out of co","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-317728","anchor_url":"https://secwatch.observer/filing/0001193125-25-317728#claim-a7a323870089529d2a8fd73df21673cb84cf4379","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000119312525317728/0001193125-25-317728-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"28d6b699aa52199cc870160d7acab68ed06f2890","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2025-08-28T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-08-25","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"Iterum Therapeutics plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"August 25, 2025, Iterum Therapeutics plc (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that, based on the closing bid price for the last 30 consecutive business days, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”) for continued listing on The Nasdaq Capital Market. The Notice does not result in the immediate delisting of the Company’s ordinary shares from The Nasdaq Capital Ma","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-111974","anchor_url":"https://secwatch.observer/filing/0000950170-25-111974#claim-28d6b699aa52199cc870160d7acab68ed06f2890","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025111974/0000950170-25-111974-index.htm"},{"fact_type":"debt_financing","fact_key":"0873209ff522af75fe4cf9f20bdfa1caabe96df2","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2025-05-19T23:59:59+00:00","payload":{"counterparty":"Pfizer Inc.","effective_date":"2025-05-13","event":"amendment","instrument_type":"unknown","interest_rate_text":"ten percent (10%) on a daily compounded basis","item_codes_triggered":["2.03"],"maturity_text":"October 25, 2029","principal_text":"$20.0 million"},"claim":"Iterum Therapeutics plc amended debt of $20.0 million with Pfizer Inc. at ten percent (10%) on a daily compounded basis maturing October 25, 2029.","evidence_excerpt":"Therapeutics International Limited (“ITIL”) and Pfizer Inc. (“Pfizer” and such agreement, the “Pfizer License Agreement”), ITIL agreed to make a regulatory milestone payment of $20.0 million to Pfizer (the “Milestone Payment”) upon the approval of oral sulopenem for commercial sale in the United States by the U.S. Food and Drug Administration (“FDA”). The Company had","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-073950","anchor_url":"https://secwatch.observer/filing/0000950170-25-073950#claim-0873209ff522af75fe4cf9f20bdfa1caabe96df2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025073950/0000950170-25-073950-index.htm"},{"fact_type":"executive_change","fact_key":"dd3bddcdb1","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2025-03-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-03-10","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"David Kelly was appointed as Chairman of the Board at Iterum Therapeutics plc.","evidence_excerpt":"the Board also appointed David Kelly, an existing director of the Board, as Chairman of the Board, effective as of March 10, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-035943","anchor_url":"https://secwatch.observer/filing/0000950170-25-035943#claim-dd3bddcdb1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025035943/0000950170-25-035943-index.htm"},{"fact_type":"executive_change","fact_key":"aca580e0fc","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2025-03-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-03-10","interim":false,"role":"Class III Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Joseph J. Whalen was appointed as Class III Director at Iterum Therapeutics plc.","evidence_excerpt":"approved the appointment of Joseph J. Whalen as a member of the Board, effective as of March 10, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-035943","anchor_url":"https://secwatch.observer/filing/0000950170-25-035943#claim-aca580e0fc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025035943/0000950170-25-035943-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"e61447e2055e04f53549f6963960a8f96c67a152","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2025-02-14T23:59:59+00:00","payload":{"company_response":"notified Nasdaq of noncompliance","compliance_status":"deficient","cure_deadline":null,"deficiency_type":"audit_committee","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"audit committee of at least three independent members","notice_date":"2025-02-14","notice_type":"noncompliance_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5605(c)(2)(A)","reported_value":"vacancy due to resignation","rule_numbers":["5605(c)(2)(A)"],"rules_cited_in_text":true},"claim":"Iterum Therapeutics plc received a nasdaq noncompliance notice notice regarding audit committee (rules 5605(c)(2)(A)).","evidence_excerpt":"February 14, 2025, Iterum Therapeutics plc (the “Company”), notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company will not be in compliance with the audit committee requirement under Nasdaq Listing Rule 5605(c)(2)(A) as of February 14, 2025, solely due to a vacancy on the audit committee (the “Audit Committee”) of the Company’s Board of Directors (the “Board”) resulting from Ronald Hunt’s resignation from the Board as disclosed in","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-021365","anchor_url":"https://secwatch.observer/filing/0000950170-25-021365#claim-e61447e2055e04f53549f6963960a8f96c67a152","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025021365/0000950170-25-021365-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"2a95374ecc73e2886c9b5fdd8f790af6acac3e13","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2025-02-14T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"audit_committee","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-02-14","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5605(c)(2)(A)"]},"claim":"Iterum Therapeutics plc received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A)).","evidence_excerpt":"February 14, 2025, Iterum Therapeutics plc (the “Company”), notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company will not be in compliance with the audit committee requirement under Nasdaq Listing Rule 5605(c","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-021365","anchor_url":"https://secwatch.observer/filing/0000950170-25-021365#claim-2a95374ecc73e2886c9b5fdd8f790af6acac3e13","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025021365/0000950170-25-021365-index.htm"},{"fact_type":"executive_change","fact_key":"e69c15f68f","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2025-02-14T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-14","interim":false,"role":"Chairman and director","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Ronald Hunt resigned as Chairman and director at Iterum Therapeutics plc.","evidence_excerpt":"On February 14, 2025, Ronald Hunt, Chairman and director of the Company, notified the Company of his resignation as Chairman and director of the Company, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-021365","anchor_url":"https://secwatch.observer/filing/0000950170-25-021365#claim-e69c15f68f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025021365/0000950170-25-021365-index.htm"},{"fact_type":"executive_change","fact_key":"7298263c55","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2024-05-31T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-05-31","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Sailaja Puttagunta resigned as Chief Medical Officer at Iterum Therapeutics plc.","evidence_excerpt":"Dr. Puttagunta, whose previously announced resignation as CMO is effective as of May 31, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-066932","anchor_url":"https://secwatch.observer/filing/0000950170-24-066932#claim-7298263c55","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024066932/0000950170-24-066932-index.htm"},{"fact_type":"earnings_release","fact_key":"1d9d5a59549aeb20c0d0e4df15237728d6480831","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2024-05-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$7.1 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-13","result_type":"reported_results","revenue_text":null},"claim":"Iterum Therapeutics plc reported first quarter ended March 31, 2024 results: net income $7.1 million.","evidence_excerpt":"iterum Therapeutics plc issued a press release announcing its financial results for the first quarter ended March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-058190","anchor_url":"https://secwatch.observer/filing/0000950170-24-058190#claim-1d9d5a59549aeb20c0d0e4df15237728d6480831","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024058190/0000950170-24-058190-index.htm"},{"fact_type":"executive_change","fact_key":"6d97c8b118","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2024-05-10T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-05-31","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Sailaja Puttagunta resigned as Chief Medical Officer at Iterum Therapeutics plc.","evidence_excerpt":"On May 8, 2024, Sailaja Puttagunta M.D. notified Iterum Therapeutics plc (the “Company”) of her decision to resign as Chief Medical Officer the Company, effective May 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-057831","anchor_url":"https://secwatch.observer/filing/0000950170-24-057831#claim-6d97c8b118","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024057831/0000950170-24-057831-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"4afcafaa94c5559ab34e0a225e4feb1ac9e8dde2","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2024-04-05T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"plan_due","cure_deadline":null,"deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2024-04-03","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"Iterum Therapeutics plc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"April 3, 2024, Iterum Therapeutics plc (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), because (i) the stockholders’ equity (deficit) of the Company of ($6,403,000) as of December 31, 2023, as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, was below the minimum stockholders’ equity requirement of $2,500,000 and (ii) the Company did not, as of April 3, 2024, meet the alternatives standards of market value of listed securities or net income from c","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-042288","anchor_url":"https://secwatch.observer/filing/0000950170-24-042288#claim-4afcafaa94c5559ab34e0a225e4feb1ac9e8dde2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024042288/0000950170-24-042288-index.htm"},{"fact_type":"earnings_release","fact_key":"f5eb0431da2326f38b70a84231a23ff0a0dce2ba","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2024-03-29T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and year ended December 31, 2023","report_date":"2024-03-28","result_type":"reported_results","revenue_text":null},"claim":"Iterum Therapeutics plc reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On March 28, 2024, Iterum Therapeutics plc issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-038414","anchor_url":"https://secwatch.observer/filing/0000950170-24-038414#claim-f5eb0431da2326f38b70a84231a23ff0a0dce2ba","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024038414/0000950170-24-038414-index.htm"},{"fact_type":"shareholder_vote","fact_key":"62c3715c46e285c850c662cfd0dc08d487b6459a","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2024-01-30T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-01-30","outcome":"failed","proposal_text":"Board Authority to Issue Ordinary Shares for Cash without First Offering Ordinary Shares to Existing Shareholders","proposal_type":"other","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"26,719","votes_against":"2,724,101","votes_for":"3,139,498","votes_withheld":null}]},"claim":"Iterum Therapeutics plc shareholders rejected Board Authority to Issue Ordinary Shares for Cash without First Offering Ordinary Shares to Existing Shareholders at the 2024-01-30 meeting.","evidence_excerpt":"The shareholders did not approve the grant to the board of directors of authority under Irish law to allot and issue an additional 5,000,000 shares (including rights to acquire such shares) for cash without first offering those shares to existing shareholders under pre-emptive rights that would otherwise apply to the issuance.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-008937","anchor_url":"https://secwatch.observer/filing/0000950170-24-008937#claim-62c3715c46e285c850c662cfd0dc08d487b6459a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024008937/0000950170-24-008937-index.htm"},{"fact_type":"executive_change","fact_key":"649e8feb67","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2023-12-29T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-12-31","interim":false,"role":"member of the Board of Directors","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mark Chin resigned as member of the Board of Directors at Iterum Therapeutics plc.","evidence_excerpt":"On December 28, 2023, Mark Chin informed management that he would be resigning as a member of the Board of Directors of Iterum Therapeutics plc (the \"Company\") with effect from December 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-073865","anchor_url":"https://secwatch.observer/filing/0000950170-23-073865#claim-649e8feb67","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023073865/0000950170-23-073865-index.htm"},{"fact_type":"earnings_release","fact_key":"e2cf025c9fe6956ea0f40d9abf3df7daaf83b74d","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2023-11-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the third quarter 2023 was $3.9 million","period_text":"the third quarter ended September 30, 2023","report_date":"2023-11-14","result_type":"reported_results","revenue_text":null},"claim":"Iterum Therapeutics plc reported the third quarter ended September 30, 2023 results: net income Net loss for the third quarter 2023 was $3.9 million.","evidence_excerpt":"Iterum Therapeutics Reports Third Quarter 2023 Financial Results","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-063350","anchor_url":"https://secwatch.observer/filing/0000950170-23-063350#claim-e2cf025c9fe6956ea0f40d9abf3df7daaf83b74d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023063350/0000950170-23-063350-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"92d9dcd031703fa839514537eb9cf8fefbc53bd9","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2023-10-02T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-09-26","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(a)(2), Nasdaq Listing Rule 5810(c)(3)(A)","reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Iterum Therapeutics plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"September 26, 2023, Iterum Therapeutics plc (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC, (“ Nasdaq ”) indicating that, based on the closing bid price for the last 30 consecutive business days, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company maintain a minimum bid price of $1.00 per share (the “ Bid Price Rule ”) for continued listing on The Nasdaq Capital Market. The Notice does not result in the immediate delisting of the Company’s ordinary shares from The Nasda","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-050856","anchor_url":"https://secwatch.observer/filing/0000950170-23-050856#claim-92d9dcd031703fa839514537eb9cf8fefbc53bd9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023050856/0000950170-23-050856-index.htm"},{"fact_type":"earnings_release","fact_key":"48a4d60513a8ecafb76f7731a9973a0575e06e08","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2023-08-11T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$12.2 million","period_text":"quarter ended June 30, 2023","report_date":"2023-08-11","result_type":"reported_results","revenue_text":null},"claim":"Iterum Therapeutics plc reported quarter ended June 30, 2023 results: net income $12.2 million.","evidence_excerpt":"Iterum Therapeutics plc issued a press release announcing its financial results for the second quarter ended June 30, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-041597","anchor_url":"https://secwatch.observer/filing/0000950170-23-041597#claim-48a4d60513a8ecafb76f7731a9973a0575e06e08","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023041597/0000950170-23-041597-index.htm"},{"fact_type":"shareholder_vote","fact_key":"9dd782cc6a6c1b9c4203a4dba399024bda028168","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2023-08-01T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-01","outcome":"failed","proposal_text":"Board Authority to Issue Ordinary Shares for Cash without First Offering Ordinary Shares to Existing Shareholders","proposal_type":"other","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"31,590","votes_against":"2,167,250","votes_for":"3,551,455","votes_withheld":"0"}]},"claim":"Iterum Therapeutics plc shareholders rejected Board Authority to Issue Ordinary Shares for Cash without First Offering Ordinary Shares to Existing Shareholders at the 2023-08-01 meeting.","evidence_excerpt":"On August 1, 2023, Iterum Therapeutics plc (the \" Company \") held an extraordinary general meeting, at which the Company’s shareholders voted on the following proposal, which is described in the Company’s definitive proxy statement, filed with the Securities and Exchange Commission on June 12, 2023. Proposal: Board Authority to Issue Ordinary Shares for Cash without First Offering Ordinary Shares to Existing Shareholders. The shareholders did not approve the grant to the board of directors of authority under Irish law to issue shares (including rights to acquire shares) for cash without first offering those shares to existing shareholders under pre-emptive rights that would otherwise apply to the issuance. This proposal required the affirmative vote of the holders of ordinary shares representing at least 75% of the votes cast on the matter to be approved. The results of the shareholders’ vote were as follows: For Against Abstain Broker Non-Votes 3,551,455 2,167,250 31,590 * * No broker","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-036485","anchor_url":"https://secwatch.observer/filing/0000950170-23-036485#claim-9dd782cc6a6c1b9c4203a4dba399024bda028168","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023036485/0000950170-23-036485-index.htm"},{"fact_type":"earnings_release","fact_key":"331612aedc63f52e7f432767155792d0103ce69f","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2023-05-12T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the first quarter 2023 was $9.9 million","period_text":"first quarter ended March 31, 2023","report_date":"2023-05-12","result_type":"reported_results","revenue_text":null},"claim":"Iterum Therapeutics plc reported first quarter ended March 31, 2023 results: net income Net loss for the first quarter 2023 was $9.9 million.","evidence_excerpt":"Iterum Therapeutics plc issued a press release announcing its financial results for the first quarter ended March 31, 2021.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-021495","anchor_url":"https://secwatch.observer/filing/0000950170-23-021495#claim-331612aedc63f52e7f432767155792d0103ce69f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023021495/0000950170-23-021495-index.htm"},{"fact_type":"governance_change","fact_key":"58e9335e035200a21c9b21af7dcc6064f72854fa","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2023-05-04T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-05-03","item_codes_triggered":["5.03"],"summary_text":"Increased authorized share capital from $1,200,000 to $1,800,000 by creating 60,000,000 additional ordinary shares"},"claim":"Iterum Therapeutics plc: Increased authorized share capital from $1,200,000 to $1,800,000 by creating 60,000,000 additional ordinary shares (effective 2023-05-03).","evidence_excerpt":"Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Amendment and Restatement of Constitution Effective as of May 03, 2023, Iterum Therapeutics plc ( the \" Company \"), amended its constitution (the “ Amended and Restated Constitution ”) following approval by its shareholders at its annual general meeting (the “ AGM ”) of a proposal to increase the Company’s authorized share capital from $1,200,000 to $1,800,000 by the creation of an additional 60,000,000 ordinary shares. A copy of the Amended and Restated Constitution is attached hereto as Exhibit 3.1 and is incorporated herein by reference.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-017662","anchor_url":"https://secwatch.observer/filing/0000950170-23-017662#claim-58e9335e035200a21c9b21af7dcc6064f72854fa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023017662/0000950170-23-017662-index.htm"},{"fact_type":"shareholder_vote","fact_key":"c93abd280d67598fa3e708e6c5de9674baa0ed9e","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2023-05-04T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-03","outcome":"failed","proposal_text":"Pre-emption Rights Opt-out Proposal","proposal_type":"other","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"143,270","votes_against":"2,253,018","votes_for":"3,533,047","votes_withheld":null}]},"claim":"Iterum Therapeutics plc shareholders rejected Pre-emption Rights Opt-out Proposal at the 2023-05-03 meeting.","evidence_excerpt":"Proposal No. 5: Pre-emption Rights Opt-out Proposal. The shareholders did not approve the grant to the board of directors of an updated authority under Irish law to issue shares (including rights to acquire shares) for cash without first offering those shares to existing shareholders under pre-emptive rights that would otherwise apply to the issuance. This proposal required the affirmative vote of the holders of ordinary shares representing at least 75% of the votes cast on the matter to be approved. The results of the shareholders’ vote were as follows: For Against Abstain Broker Non-Votes 3,533,047 2,253,018 143,270 *","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-017662","anchor_url":"https://secwatch.observer/filing/0000950170-23-017662#claim-c93abd280d67598fa3e708e6c5de9674baa0ed9e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023017662/0000950170-23-017662-index.htm"},{"fact_type":"shareholder_vote","fact_key":"87d6caf88bdae5d2ee53c0b1a44411df6f6c5378","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2023-05-04T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-03","outcome":"passed","proposal_text":"Directors’ Allotment Authority Proposal","proposal_type":"other","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"130,841","votes_against":"2,272,868","votes_for":"3,525,626","votes_withheld":null}]},"claim":"Iterum Therapeutics plc shareholders approved Directors’ Allotment Authority Proposal at the 2023-05-03 meeting.","evidence_excerpt":"Proposal No. 4: Directors’ Allotment Authority Proposal. The shareholders approved the grant to the board of directors of an updated authority under Irish law to allot and issue shares, warrants, convertible instruments and options. The results of the shareholders’ vote were as follows: For Against Abstain Broker Non-Votes 3,525,626 2,272,868 130,841 *","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-017662","anchor_url":"https://secwatch.observer/filing/0000950170-23-017662#claim-87d6caf88bdae5d2ee53c0b1a44411df6f6c5378","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023017662/0000950170-23-017662-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7b324b218bb6c7aa2f233b5c9edbda52f435a07b","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2023-05-04T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-03","outcome":"passed","proposal_text":"Authorized Share Capital Increase Proposal","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"26,976","votes_against":"2,340,718","votes_for":"3,561,641","votes_withheld":null}]},"claim":"Iterum Therapeutics plc shareholders approved Authorized Share Capital Increase Proposal at the 2023-05-03 meeting.","evidence_excerpt":"Proposal No. 3: Authorized Share Capital Increase Proposal . The shareholders approved an increase in the authorized share capital of the Company from $1,200,000 to $1,800,000 by the creation of an additional 60,000,000 ordinary shares. The results of the shareholders’ vote were as follows: For Against Abstain Broker Non-Votes 3,561,641 2,340,718 26,976 *","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-017662","anchor_url":"https://secwatch.observer/filing/0000950170-23-017662#claim-7b324b218bb6c7aa2f233b5c9edbda52f435a07b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023017662/0000950170-23-017662-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7e868b66b1599ae145895ffd78948e490a2ed45e","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2023-05-04T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-03","outcome":"passed","proposal_text":"Ratification of Appointment of Independent Registered Public Accounting Firm and Authorization to Approve Remuneration","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"180,332","votes_against":"890,901","votes_for":"4,858,102","votes_withheld":null}]},"claim":"Iterum Therapeutics plc shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm and Authorization to Approve Remuneration at the 2023-05-03 meeting.","evidence_excerpt":"Proposal No. 2: Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm for 2023 and Authorization of the Board of Directors to Approve the Remuneration of the Independent Registered Public Accounting Firm. The shareholders ratified, in a non-binding vote, the appointment of KPMG as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2023 and authorized the Company’s board of directors, acting through its audit committee, to set the independent registered public accounting firm’s remuneration. The results of the shareholders’ vote were as follows: For Against Abstain Broker Non-Votes 4,858,102 890,901 180,332 *","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-017662","anchor_url":"https://secwatch.observer/filing/0000950170-23-017662#claim-7e868b66b1599ae145895ffd78948e490a2ed45e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023017662/0000950170-23-017662-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ebb6ea13268ca854d051af0b71baaebce60e7864","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2023-05-04T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-03","outcome":"passed","proposal_text":"Election of Class II Directors","proposal_type":"director_election","results":[{"broker_non_votes":"3,160,411","subject":"Beth P. Hecht","votes_abstain":"147,135","votes_against":"1,108,371","votes_for":"1,513,418","votes_withheld":null},{"broker_non_votes":"3,160,411","subject":"Michael W. Dunne","votes_abstain":"143,618","votes_against":"974,083","votes_for":"1,651,223","votes_withheld":null}]},"claim":"Iterum Therapeutics plc shareholders approved Election of Class II Directors at the 2023-05-03 meeting.","evidence_excerpt":"Proposal No. 1: Election of Directors. The shareholders elected, by separate resolutions, Beth P. Hecht and Michael W. Dunne to the Company’s board of directors as Class II directors, each to serve for a three-year term expiring at the Company's 2026 annual general meeting of shareholders. The results of the shareholders’ vote for the election of such Class II directors were as follows: Nominee For Against Abstain Broker Non-Votes Beth P. Hecht 1,513,418 1,108,371 147,135 3,160,411 Michael W. Dunne 1,651,223 974,083 143,618 3,160,411","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-017662","anchor_url":"https://secwatch.observer/filing/0000950170-23-017662#claim-ebb6ea13268ca854d051af0b71baaebce60e7864","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023017662/0000950170-23-017662-index.htm"},{"fact_type":"earnings_release","fact_key":"c8b592e351269ff61fe2455895ad3ae9f5e11c1d","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2023-03-16T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the fourth quarter and full year 2022 was $5.1 million and $44.4 million, respectively, compared to a net l","period_text":"fourth quarter and year ended December 31, 2022","report_date":"2023-03-16","result_type":"reported_results","revenue_text":null},"claim":"Iterum Therapeutics plc reported fourth quarter and year ended December 31, 2022 results: net income Net loss for the fourth quarter and full year 2022 was $5.1 million and $44.4 million, respectively, compared to a net l.","evidence_excerpt":"Iterum Therapeutics plc issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-008293","anchor_url":"https://secwatch.observer/filing/0000950170-23-008293#claim-c8b592e351269ff61fe2455895ad3ae9f5e11c1d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023008293/0000950170-23-008293-index.htm"},{"fact_type":"earnings_release","fact_key":"6de06992ada7ad67687bd3c94b4519f3b024e2cc","cik":1659323,"ticker":"ITRMF","company_name":"Iterum Therapeutics plc","filed_at":"2022-11-10T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the third quarter ended September 30, 2022","report_date":"2022-11-10","result_type":"reported_results","revenue_text":null},"claim":"Iterum Therapeutics plc reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-22-024154","anchor_url":"https://secwatch.observer/filing/0000950170-22-024154#claim-6de06992ada7ad67687bd3c94b4519f3b024e2cc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017022024154/0000950170-22-024154-index.htm"}]}